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There is increasing evidence that the presence of an ongoing systemic inflammatory response is associated with poor outcome in
patients with advanced cancer. The aim of the present study was to examine whether an inflammation-based prognostic score
(Glasgow Prognostic score, GPS) was associated with survival, in patients with inoperable gastro-oesophageal cancer. Patients
diagnosed with inoperable gastro-oesophageal carcinoma and who had measurement of albumin and C-reactive protein
concentrations, at the time of diagnosis, were studied (n¼258). Clinical information was obtained from a gastro-oesophageal cancer
database and analysis of the case notes. Patients with both an elevated C-reactive protein (410mgl
 1) and hypoalbuminaemia
(o35gl
 1) were allocated a GPS score of 2. Patients in whom only one of these biochemical abnormalities was present were
allocated a GPS score of 1, and patients with a normal C-reactive protein and albumin were allocated a score of 0. On multivariate
survival analysis, age (hazard ratio (HR) 1.22, 95% CI 1.02–1.46, Po0.05), stage (HR 1.55, 95% CI 1.30–1.83, Po0.001), the GPS
(HR 1.51, 95% CI 1.22–1.86, Po0.001) and treatment (HR 2.53, 95% CI 1.80–3.56, Po0.001) were significant independent
predictors of cancer survival. A 12-month cancer-specific survival in patients with stage I/II disease receiving active treatment was 67
and 60% for a GPS of 0 and 1, respectively. For stage III/IV disease, 12 months cancer-specific survival was 57, 25 and 12% for a GPS
of 0, 1 and 2, respectively. In the present study, the GPS predicted cancer-specific survival, independent of stage and treatment
received, in patients with inoperable gastro-oesophageal cancer. Moreover, the GPS may be used in combination with conventional
staging techniques to improve the prediction of survival in patients with inoperable gastro-oesophageal cancer.
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Gastro-oesophageal cancer is the third commonest cause of cancer
death in the UK. Each year, there are approximately 16500 new
cases and over 13000 deaths attributable to the disease. Overall
survival is poor with the majority of patients presenting with
advanced, inoperable disease and less than 15% surviving 5 years
(Cancerstats, 2004; www.cancerresearchuk.org). Despite an often
short median and poor overall survival, there is marked
heterogeneity in the duration of survival among patients. There-
fore, there is continuing interest in prognostic factors to permit
more accurate patient stratification and which will improve clinical
decision making, and possibly contribute to more rational study
design and analysis (Allgayer et al, 1997).
A small proportion of patients with inoperable, but localised
oesophageal cancers may be suitable for potentially curative
nonsurgical treatment with (chemo) radiation therapy; however,
most frequently, these modalities are used in palliation. While such
palliative treatment may confer a small survival advantage over
best supportive care, it is primarily directed towards symptom
relief (Middleton and Cunningham, 1995; Pyrhonen et al, 1995).
This however may sometimes be at the expense of toxicity (Ross
et al, 2002; Harvey et al, 2004) and therefore the appropriate
selection of patients, most likely to benefit is of considerable
importance.
Previous studies have indicated that weight loss or performance
status may be associated with treatment outcome and survival in
inoperable oesophago-gastric cancer (Andreyev et al, 1998; Chau
et al, 2004). However, the use of weight loss as a prognostic factor
remains problematical since it is often not well defined and
subject to bias (Morgan et al, 1980; Rowland, 1990). Furthermore,
performance status is recognised to be subjective (Ando et al,
2001).
There is increasing evidence that the presence of a systemic
inflammatory response, as evidenced by elevated concentrations
of C-reactive protein, is a prognostic factor independent of stage,
performance status and weight loss in patients with advanced
cancer (O’Gorman et al, 2000; Scott et al, 2002; Maltoni et al,
2005). Recently, we have shown that an elevated C-reactive protein
and hypoalbuminaemia (using standardised assays and accepted
thresholds for C-reactive protein and albumin concentrations)
may be combined to form a score, the Glasgow Prognostic score
(GPS), which has prognostic value, independent of stage and
performance status, in patients with inoperable non-small-cell
lung cancer (Forrest et al, 2003, 2004).
The aim of the present study was to assess the relationship
between the GPS and survival in patients with inoperable gastro-
oesophageal cancer.
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Patients
Patients diagnosed with inoperable gastro-oesophageal carcinoma,
attending the upper GI surgical unit in the Royal Infirmary,
Glasgow between the 1 January 2000 and the 31 December 2004
and who had a pretreatment measurement of C-reactive protein
and albumin were studied. Patients were staged using a combina-
tion of endoscopy, CT scan of chest and abdomen, laparoscopy
and endoscopic ultrasound, in addition to clinical assessment. The
specific use of these modalities was dependent upon the clinical
tumour features and where appropriate, assessment of fitness,
cardiac and lung function testing was also performed.
The extent of tumour spread was recorded using the TNM stage.
Tumours around the gastro-oesophageal junction were further
classified according to site, using the Siewert system; type 1 and
2 lesions of the gastro-oesophageal junction were designated as
cancers of the oesophagus. Type 3 tumours of the cardia were
designated as gastric cancers.
Patients identified as being suitable for resection or radical,
nonsurgical treatment given with curative intent were excluded
from this analysis, as were patients who had any form of chronic
inflammatory disease (e.g. vasculitis, connective tissue disorders,
rheumatological conditions) and those with cancers arising in other
organs. Therefore, the study group comprised patients unsuitable
for either surgical resection or radical, nonsurgical treatment.
Patients who underwent palliative chemotherapy, palliative
radiotherapy or endoscopic laser were considered to have had
‘active’ treatment. Patients receiving palliative care (symptom
control) were considered to have had ‘supportive’ treatment. The
‘active’ treatment group was further subdivided into: chemotherapy
based (chemotherapy7radiotherapy7endoscopic treatment),
radiotherapy based (radiotherapy7endoscopic treatment) and
endoscopic laser (laser7stent).
The study was approved by the Research Ethics Committee of
Glasgow Royal Infirmary.
Methods
Routine laboratory measurements of C-reactive protein and albumin
at the time of diagnosis were carried out. The limit of detection of
the C-reactive protein assay was o6mgl
 1. The coefficients of
variation of these methods, over the range of measurements, was less
than 5% as established by routine quality control.
The GPS was constructed as previously described (Forrest et al,
2003, 2004). Briefly, patients with both an elevated C-reactive
protein (410mgl
 1) and hypoalbuminaemia (o35gl
 1) were
allocated a score of 2. Patients in whom only one of these
biochemical abnormalities was present were allocated a score of 1.
Patients in whom neither of these abnormalities was present were
allocated a score of 0.
Statistics
Data are presented as median and 95% CI. Grouping of the variables
was carried out using standard thresholds. Univariate survival
analysis was performed using the Kaplan–Meier method with the
logrank test. Multivariate survival analysis and calculation of hazard
ratios (HR) were performed using a Cox regression model including
all covariates that were significant on univariate analysis. Deaths up
to 30 June 2005 were included in the analysis. Analysis was
performed using SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
The characteristics and survival analysis of patients with inoper-
able gastro-oesophageal cancer (n¼258) are shown in Table 1.
The majority were male, over the age of 65 years, had stage IV
disease and had tumours of the oesophagus. Patients with stage I
and II disease were not considered suitable for surgery or radical
chemoradiation due to comorbidity. The majority of patients had
an abnormal GPS. Of the 52 patients with hypoalbuminaemia,
45 (86%) had an elevated C-reactive protein concentration. In
total, 195 patients (76%) received active treatment and the
remainder received supportive care only.
The minimum follow-up was 6 months or until date of death; the
median follow-up of the survivors was 12 months. During this
period, 211 (82%) patients died: 202 patients of their cancer and
nine of intercurrent disease. On univariate analysis, tumour site
(Po0.05), stage (Po0.001), alkaline phosphatase (Po0.05), the
GPS (Po0.001, Figure 1) and treatment (Po0.001) were significant
predictors of cancer-specific survival. On multivariate analysis,
age (Po0.05), stage (Po0.001), the GPS (Po0.001) and treatment
(Po0.001) were significant independent predictors of cancer-
specific survival (Table 2).
The characteristics and survival analysis of those patients
receiving active treatment (n¼195) are shown in Table 3. On
multivariate analysis, stage (Po0.001), the GPS (Po0.001,
Table 1 Clinical characteristics and cancer-specific survival in patients
with inoperable gastro-oesophageal cancer: univariate survival analysis
Patients 258
(100%)
Survival
(months)
median (95% CI) P-value
Age (years)
o65 91 (35) 8.0 (7.0–9.0)
65–74 64 (25) 6.6 (2.5–10.8)
475 103 (40) 7.4 (4.8–10.1) 0.664
Sex
Male 166 (64) 7.4 (5.7–9.1)
Female 92 (36) 8.0 (6.2–9.9) 0.728
Tumour type
Adenocarcinoma 187 (73) 8.2 (6.2–9.6)
Squamous 71 (27) 6.6 (4.9–8.3) 0.979
Tumour site
Oesophagus 142 (55) 8.9 (6.8–11.1)
Gastric 116 (45) 6.6 (4.0–9.3) 0.042
TNM stage
I 29 (11) 20.5 (13.3–27.7)
II 27 (11) 11.8 (8.3–15.3)
III 64 (25) 9.8 (8.1–11.5)
IV 138 (53) 4.5 (2.4–6.5) o0.001
Alkaline phosphatase (Ul
 1)
Tertile 1
(n¼85)
145 (19–176)
a 8.4 (6.7–10.2)
Tertile 2
(n¼85)
199 (176–233) 8.9 (6.8–11.1)
Tertile 3
(n¼84)
325 (235–2396) 5.0 (2.1–7.9) 0.050
GPS
0 92 (36) 13.6 (9.2–18.1)
1 121 (47) 6.3 (4.2–8.5)
2 45 (17) 2.4 (0.5–4.4) o0.001
Treatment
Active 195 (76) 10.1 (8.6–11.6)
Supportive 63 (24) 2.1 (1.3–2.8) o0.001
aMedian (range). GPS¼Glasgow Prognostic score.
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sFigure 2) and treatment (Po0.01) were significant independent
predictors of cancer-specific survival.
The characteristics and survival analysis of those patients
receiving supportive treatment (n¼63) are shown in Table 4. On
multivariate analysis, only stage (Po0.05) was a significant
independent predictor of cancer-specific survival.
The relationship between stage, the GPS and the 12-month
survival rate in those patients receiving active treatment is shown
in Table 5. The 12-month cancer-specific survival in patients with
stage I/II disease receiving active treatment was 67 and 60% for a
GPS of 0 and 1, respectively. For stage III/IV disease, the 12-month
cancer-specific survival was 57, 25 and 12% for a GPS of 0, 1 and 2,
respectively.
DISCUSSION
In the present study the presence of a systemic inflammatory
response, reflected in the GPS, predicts cancer-specific survival,
independent of tumour stage, in patients with inoperable gastro-
oesophageal cancer. Moreover, we have shown how the GPS might
be used in combination with stage to improve the prediction of
survival. It may be that this simply derived inflammation-based
score will be a useful tool in the prediction of survival and possible
stratification, at diagnosis, of patients with inoperable gastro-
oesophageal cancer.
It was of interest that, in the present study, only seven
(14%) patients had hypoalbuminaemia in the absence of an
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Figure 1 The relationship between an inflammation-based prognostic
score (GPS, 0, 1, 2 from top to bottom) and survival in patients with
inoperable gastro-oesophageal cancer.
Table 2 Clinical characteristics and cancer-specific survival in patients with inoperable gastro-oesophageal cancer: multivariate survival analysis
Patients (n¼258) Hazard ratio (95% CI) P-value
Age (o65/65–74/475 years) 91/64/103 1.22 (1.02–1.46) 0.032
Sex (male/female) 166/92 1.07 (0.80–1.45) 0.642
Tumour type (adenocarcinoma/squamous) 187/71 1.28 (0.87–1.89) 0.210
Tumour site (oesophagus/gastric) 142/116 1.36 (0.96–1.92) 0.087
TNM stage (I/II/III/IV) 29/27/64/138 1.55 (1.30–1.83) o0.001
GPS (0/1/2) 92/121/45 1.51 (1.22–1.86) o0.001
Alkaline phosphatase (Ul
 1) (Tertiles 1/2/3) 85/85/84 1.10 (0.92–1.32) 0.300
Treatment (active/supportive) 195/63 2.53 (1.80–3.56) o0.001
GPS¼Glasgow Prognostic score.
Table 3 Clinical characteristics and cancer-specific survival in patients with inoperable gastro-oesophageal cancer receiving active treatment: multivariate
survival analysis
Patients (n¼195) Hazard ratio (95% CI) P-value
Age (o65/65–74/475 years) 74/49/72 1.13 (0.88–1.45) 0.354
Sex (male/female) 129/66 1.14 (0.80–1.65) 0.465
Tumour type (adenocarcinoma/squamous) 142/53 1.39 (0.89–2.17) 0.154
Tumour site (oesophagus/gastric) 114/81 1.27 (0.85–1.89) 0.249
TNM stage (I/II/III/IV) 27/20/51/97 1.66 (1.36–2.03) o0.001
GPS (0/1/2) 78/89/28 1.75 (1.35–2.26) o0.001
Alkaline phosphatase (U/l) (Tertiles 1/2/3) 67/64/60 0.97 (0.78–1.21) 0.788
Treatment (chemotherapy/radiotherapy/endoscopic) 102/33/60 1.48 (1.15–1.90) 0.003
GPS¼Glasgow Prognostic score.
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Figure 2 The relationship between an inflammation-based prognostic
score (GPS, 0, 1, 2 from top to bottom) and survival in patients with
inoperable gastro-oesophageal cancer receiving active treatment.
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selevated C-reactive protein concentration. This is consistent
with the concept that the development of hypoalbuminaemia is
often secondary to an ongoing systemic inflammatory response
(McMillan et al, 2001; Al Shaiba et al, 2004). Glasgow Prognostic
score may thus reflect both the presence of an ongoing systemic
inflammatory response (C-reactive protein) and the progressive
nutritional decline (albumin) of the patient with advanced cancer.
The mechanism by which a systemic inflammatory response
might influence cancer survival in these patients is not clear.
However, it may be that the presence of a systemic inflammatory
response and the associated nutritional decline (McMillan et al,
1998; Scott et al, 2002) influences tolerance and compliance
with active treatment (Bromwich et al, 2004; Forrest et al, 2004).
Indeed, Andreyev et al (1998) reported that the poorer outcome
of chemotherapy in advanced gastrointestinal cancer patients
with weight loss appeared to be as a result of receiving less
chemotherapy, due to toxicity, rather than poorer tumour
response.
When the relationship between the GPS and 12-month survival
rate was examined in patients with stage III/IV disease receiving
active treatment, there was approximately a five-fold decrease in
the survival rate between those patients with a GPS of 0 (57%) and
those with a GPS of 2 (12%). This suggests that there is a subgroup
of patients who derive little survival benefit from active treatment.
However, it is important to remember that treatment in these
patients is given with palliative intent and survival data do not
reflect end points of palliation. This aspect is being explored
further in ongoing work, however the identification of a patient
subgroup with limited prognosis, through the use of a simple
reliable prognostic score, may aid the treatment decision-making
process. In particular, it would seem inappropriate to subject such
patients to potentially toxic treatments if simpler palliative options
exist.
In summary, the prognosis for patients diagnosed with
inoperable gastro-oesophageal cancer, even with active treatment,
remains poor. The presence of a systemic inflammatory response
(an elevated GPS) appears to be a useful indicator of outcome
among these patients, independent of stage. Moreover, the GPS has
the advantage of being simple to measure, routinely available and
well standardised.
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